Furthermore, Peretz and coworkers [43] reported that the time from a MAO-B inhibitor prescription until the initiation of dopamine agonists or levodopa therapy was longer in Parkinson’s patients treated with selegiline in comparison with rasagiline treatment. This evidence concerns the gene MAOB and Parkinsonism.